Trivalent chromium and the diabetes prevention program

The Diabetes Prevention Program is a new, 150 million dollar, NIH-sponsored study designed to determine whether non-insulin-dependent diabetes mellitus can be prevented or delayed in persons with impaired glucose tolerance. Four thousand subjects will be randomly assigned to one of four study groups...

Full description

Saved in:
Bibliographic Details
Published inMedical hypotheses Vol. 49; no. 1; pp. 47 - 49
Main Author Linday, L.A.
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 01.07.1997
Elsevier
Subjects
Biological and medical sciences
Chromans - pharmacology
Chromium - adverse effects
Chromium - pharmacology
Clinical Protocols
Complementary Therapies
Diabetes Mellitus, Type 2 - etiology
Diabetes Mellitus, Type 2 - prevention & control
Diabetes. Impaired glucose tolerance
Diet
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Exercise
Glucose Intolerance - complications
Glucose Intolerance - drug therapy
Humans
Hypoglycemic Agents - pharmacology
Management. Various non-drug treatments. Langerhans islet grafts
Medical sciences
Metformin - pharmacology
Safety
Thiazoles - pharmacology
Thiazolidinediones
Troglitazone
Endocrinopathy
Human
Prevention
Diet therapy
Chromium
Supplementation
Non insulin dependent diabetes
Online AccessGet full text

Cover

More Information
Summary:The Diabetes Prevention Program is a new, 150 million dollar, NIH-sponsored study designed to determine whether non-insulin-dependent diabetes mellitus can be prevented or delayed in persons with impaired glucose tolerance. Four thousand subjects will be randomly assigned to one of four study groups and followed for 4.5 years. Study groups include intensive lifestyle intervention with diet and exercise; metformin (Glucophage®) or troglitazone (an investigational drug) with standard diet and exercise; and a control group. Insulin resistance is an important pathogenic factor in impaired glucose tolerance. Trivalent chromium, a dietary supplement that potentiates the action of insulin, was not included in the program. Like metformin and troglitazone, trivalent chromium decreases insulin resistance and has an acceptable side-effect profile; furthermore, it is available at a fraction of their cost. Trivalent chromium should have been included in the Diabetes Prevention Program; it is unfortunate that it was omitted.
ISSN:0306-9877
1532-2777
DOI:10.1016/S0306-9877(97)90251-6